MNPR - Monopar Therapeutics
47.7
-0.810 -1.698%
Share volume: 1,504
Last Updated: Wed 05 Feb 2025 07:30:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.07%
PREVIOUS CLOSE
CHG
CHG%
$48.51
-0.81
-1.67%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-05-09 | 2023-08-10 | 2023-11-09 | 2024-11-08 | 2024-05-09 | 2024-08-09 | 2024-11-08 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.525 M | 2.328 M | 2.066 M | 1.912 M | 1.723 M | 1.789 M | 1.575 M | |
| Selling general and admin | 871.675 K | 733.496 K | 749.474 K | 876.397 K | 757.281 K | 657.806 K | 590.624 K | |
| Research and development | 1.653 M | 1.595 M | 1.317 M | 1.036 M | 966.110 K | 1.131 M | 984.278 K | |
| Total expenses | 2.525 M | 2.328 M | 2.066 M | 1.912 M | 1.723 M | 1.789 M | 1.575 M | |
| -7.80% | -11.26% | -7.45% | -9.86% | 3.79% | -11.96% | |||
| Operating income | -2.525 M | -2.328 M | -2.066 M | -1.912 M | -1.723 M | -1.789 M | -1.575 M | |
| Ebit | -2.525 M | -2.328 M | -2.066 M | -1.912 M | -1.723 M | -1.789 M | -1.404 M | |
| Pretax income | -2.435 M | -2.200 M | -1.954 M | -1.814 M | -1.641 M | -1.715 M | -1.304 M | |
| -9.63% | -11.19% | -7.16% | -9.52% | 4.51% | -23.96% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.435 M | -2.200 M | -1.954 M | -1.814 M | -1.641 M | -1.715 M | -1.304 M | |
| 9.63% | 11.19% | 7.16% | 9.52% | -4.51% | 23.96% |